ArticleCancer science2026
Machine Learning-Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The immune microenvironment contributes substantially to the biological and clinical heterogeneity of multiple myeloma (MM), yet immune-related molecular biomarkers with reproducible prognostic value remain limited. Here, we developed a 12-gene immune-related gene signature (IRGS) using an integrative machine-learning framework and evaluated its prognostic performance across multiple MM cohorts. The IRGS consistently stratified overall survival and remained independently associated with outcome after adjustment for established clinical covariates. Its prognostic discrimination was comparable to that of IFM15 and generally exceeded that of MRCIX6 and a mitophagy-related signature across the evaluated validation datasets. Single-cell RNA sequencing further revealed marked cell type-dependent variation in the activity of the 12-gene module, with comparatively low activity in plasma cells and higher activity in several non-plasma compartments, indicating that the bulk-derived IRGS reflects a multicellular bone marrow transcriptional context rather than an exclusively malignant plasma cell intrinsic program. Somatic mutation analysis identified distinct mutational patterns between IRGS-defined groups, including relative enrichment of DIS3 mutations in the low-IRGS group and MUC16 mutations in the high-IRGS group, together with a modestly higher tumor mutational burden in low-IRGS patients. Transcriptome-based drug-response prediction further suggested differential therapeutic vulnerabilities, with high- and low-IRGS groups showing distinct predicted sensitivity patterns across apoptosis-, DNA damage-, BET-, checkpoint-, and replication-stress-related agents. Collectively, these findings define the IRGS as a complementary immune-associated molecular biomarker for prognostic stratification in MM and provide a framework linking prognosis with multicellular transcriptional context, somatic mutational characteristics, and candidate therapeutic vulnerabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.